IgA Nephropathy
Conditions
Interventions
IgA Nephropathy group:null
Non-IgA Nephropathy group:null
Health control group:null
Sponsors
The second affiliated Hospital of Air Force military Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.IgAN group membership criteria: a) 18-70 years of age, regardless of gender. b) Renal biopsy was performed during hospitalization, which was diagnosed as IgAN and no IgM immune complex deposition. c) voluntarily participate in the trial and sign an informed consent form. 2.N-IgAN group membership criteria: a) 18-70 years of age, regardless of gender. b) pathological examination of renal biopsy during hospitalization showed that immune complex deposition was found under immunofluorescence, but not IgA immune complex. c) sign the informed consent. 3.HC group membership criteria: a) 1:1 matching with IgAN group by age and sex. b) No history of chronic kidney disease. c) sign the informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria: this study sets the overall exclusion criteria, that is, those who meet any of the following will not be included in this study: a) Secondary glomerulonephritis and renovascular diseases. b) dramatic changes of eGFR > 30% in the first 3 months, renal failure (eGFR < 30ml/min), dialysis or renal transplantation. c) use of systemic antibiotics or probiotics or preparations containing cathartic ingredients within 3 months prior to enrollment. d) systemic immunosuppressive therapy, including glucocorticoids, cyclosporine, tacrolimus, mycophenolate mofetil, etc. e) the presence of other diseases: diabetes, malignant tumors, acute digestive diseases, acute or chronic systemic infectious diseases, autoimmune diseases, liver diseases (including viral hepatitis, liver cirrhosis), severe heart diseases, infectious diseases (acquired immunodeficiency syndrome, syphilis, hepatitis B, hepatitis C, tuberculosis, etc.), history of drug or alcohol abuse. f) Cognitive impairment, unable to cooperate with the completion of the questionnaire. g) failure to communicate or comply with all research requirements, pregnancy and refusal to provide informed consent that researchers consider inappropriate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gliadin IgA antibody;Gluten protein intake; | — |
Secondary
| Measure | Time frame |
|---|---|
| 16s rRNA sequencing;Metabolite detection; | — |
Countries
China
Contacts
Public Contactzhao jie
The second affiliated Hospital of Air Force military Medical University
Outcome results
None listed